Qingdao Haier Biomedical Co Ltd Total Assets

Latest as of June 2026: CN¥5.83 Billion CNY ≈ $852.63 Million USD

Qingdao Haier Biomedical Co Ltd total assets. Based on the latest financial reports, Qingdao Haier Biomedical Co Ltd (688139) holds total assets worth CN¥5.83 Billion CNY (≈ $852.63 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 688139 market cap overview for the company's overall valuation and market capitalisation.

Total Assets of Qingdao Haier Biomedical Co Ltd (2016–2025)

Total assets of Qingdao Haier Biomedical Co Ltd from 2016 to 2025. This chart illustrates how Qingdao Haier Biomedical Co Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Qingdao Haier Biomedical Co Ltd for real-time trading data and today's change.

Qingdao Haier Biomedical Co Ltd - Asset Composition Analysis

Qingdao Haier Biomedical Co Ltd Total Assets Breakdown (December 2025)

Qingdao Haier Biomedical Co Ltd total assets breakdown as of December 2025. Qingdao Haier Biomedical Co Ltd's total assets of CN¥5.83 Billion consist of 45.9% current assets and 54.1% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 14.6%
Accounts Receivable CN¥404.42 Million 7.0%
Inventory CN¥345.47 Million 6.0%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥360.50 Million 6.2%
Goodwill CN¥758.24 Million 13.1%

Asset Composition Trend (2016–2025)

This chart illustrates how Qingdao Haier Biomedical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 688139 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Qingdao Haier Biomedical Co Ltd's current assets represent 45.9% of total assets in 2025, a decrease from 90.1% in 2016.
  • Cash Position: Cash and equivalents constituted 14.6% of total assets in 2025, up from 14.2% in 2016.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 1.0% in 2016.
  • Asset Diversification: The largest asset category is goodwill at 13.1% of total assets.

Qingdao Haier Biomedical Co Ltd Competitors by Total Assets

Key competitors of Qingdao Haier Biomedical Co Ltd based on total assets are shown below.

Company Country Total Assets
Cochlear Ltd
AU:COH
Australia AU$2.83 Billion
Vitrolife AB
ST:VITR
Sweden Skr11.30 Billion
Sinocare Inc
SHE:300298
China CN¥6.25 Billion
Shanghai Sanyou Medical Co Ltd
SHG:688085
China CN¥2.34 Billion
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
China CN¥7.51 Billion
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
China CN¥1.79 Billion
TAIDOC TECHNOLOGY CORP
TW:4736
Taiwan NT$13.07 Billion
SS Innovations International Inc. Common Stock
NASDAQ:SSII
USA $96.98 Million

Qingdao Haier Biomedical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.66 2.91 2.90
Quick Ratio 2.34 2.57 2.55
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥1.75 Billion CN¥1.71 Billion CN¥2.22 Billion

Qingdao Haier Biomedical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Qingdao Haier Biomedical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.22
Latest Market Cap to Assets Ratio 0.27
Asset Growth Rate (YoY) 0.1%
Total Assets CN¥5.79 Billion
Market Capitalization $1.55 Billion USD

Valuation Analysis

Below Book Valuation: The market values Qingdao Haier Biomedical Co Ltd's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Qingdao Haier Biomedical Co Ltd's assets grew by 0.1% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Qingdao Haier Biomedical Co Ltd (2016–2025)

The table below shows the annual total assets of Qingdao Haier Biomedical Co Ltd from 2016 to 2025.

Year Total Assets Change
2025-12-31 CN¥5.79 Billion
≈ $847.48 Million
+0.07%
2024-12-31 CN¥5.79 Billion
≈ $846.89 Million
+4.74%
2023-12-31 CN¥5.53 Billion
≈ $808.58 Million
+0.67%
2022-12-31 CN¥5.49 Billion
≈ $803.21 Million
+12.02%
2021-12-31 CN¥4.90 Billion
≈ $717.00 Million
+24.28%
2020-12-31 CN¥3.94 Billion
≈ $576.93 Million
+29.69%
2019-12-31 CN¥3.04 Billion
≈ $444.85 Million
+36.46%
2018-12-31 CN¥2.23 Billion
≈ $325.99 Million
+87.10%
2017-12-31 CN¥1.19 Billion
≈ $174.23 Million
+25.43%
2016-12-31 CN¥949.27 Million
≈ $138.91 Million
--

About Qingdao Haier Biomedical Co Ltd

SHG:688139 China Medical Devices
Market Cap
$1.55 Billion
CN¥10.56 Billion CNY
Market Cap Rank
#6856 Global
#1386 in China
Share Price
CN¥33.38
Change (1 day)
-1.45%
52-Week Range
CN¥24.70 - CN¥37.36
All Time High
CN¥147.76
About

Qingdao Haier Biomedical Co.,Ltd engages in the research and development, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples in China and internationally. The company offers ULT freezers, pharmacy refrigerators, freezers, automatic storage solutions, cryogenics, active temperature controlled RKN containers, and RTMD products; and CO2 incubation, standard … Read more